Data sets produced at the Texas A&M Tissue Chip Testing Center and at the University of Pittsburgh Drug Discovery Institute.
|View/Edit||Study Name||Start Date||Study Types||Experimental Models||Model Types||Disease(s)||Data Points||Data Points (omic)||Images||Videos||Plate Maps||Plate Reader Files||Supporting Data Files||Description||Reproducibility Status||Center||Data Entry||Review||Sign Off Date||Data Provider||ID|
|View/Edit||TCTC Reference Study||2018-01-30||CC||SQL-SAL 1.5||Fluidic-3D||-No Diseases-||329||0||0||0||0||0||0||This study is a reference study done at the UPDDI for comparison with the SQL-SAL 1.5 models run for the TCTC project. Method: Determine chip to chip reproducibility in vehicle treated (1% DMSO) and 40 µM tolcapone treated SQL-Sal 1.5 devices during 14 day incubation. Results: chip to chip variation was at excellent to acceptable levels for albumin, urea and LDH. Comment: previous studies in this model showed significant reduction in liver functions at 88 and 220 uM tolcapone. The lack of the effect at 40 uM should be retested.||UPDDI||Dillon Gavlock||4||2018-08-30||Taylor_MPS||40|
|View/Edit||TCTC Training||2018-02-27||TOX||SQL-SAL 1.5||Fluidic-3D||-No Diseases-||126||0||0||0||0||0||0||Purpose: The goal of this experiment was to educate Courtney Sakolish from Texas A&M University on the construction and use of the SQL-SAL 1.5 liver model in a commercial Nortis devices. Methods: The SQL-SAL 1.5 liver model was constructed in 6 Nortis devices for 14 day treatment to vehicle control or 88 and 220 μM tolcapone. Results: Albumin, urea synthesis was decreased, LDH release was increased in devices treated to tolcapone as compared to vehicle only treated devices.||UPDDI||Dillon Gavlock||4||2018-09-18||Taylor_MPS||152|